FDA holds meeting to determine if opioid limits should be set

FDA holds meeting to determine if opioid limits should be set

Publication date: Jun 12, 2019

The FDA has started its two-day advisory committee meeting to determine if higher doses of opioids should be limited or removed from the market.

During the meeting, the FDA is soliciting feedback from clinical, patient, public health and research communities to better understand current clinical use of higher-dose opioids, situations that may warrant the use of higher doses and frequency of harm associated with higher doses.

Concepts Keywords
FDA Heroin
Frequency Ketamine
Intelligence Pain management
KLAS Analgesic
Opioid Morphinans
Opioids Ketones
Pain Management Euphoriants
Protocol RTT
Opioids
Psychoactive drugs
Drugs
Surgery
Pain management

Semantics

Type Source Name
gene UNIPROT PYCARD
gene UNIPROT STS
gene UNIPROT SET
disease MESH communities
drug DRUGBANK Tropicamide
disease DOID Analgesia
disease MESH cancer
disease DOID cancer
drug DRUGBANK N-acetylsulfanilyl chloride

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *